Veterinary and Comparative Oncology

Papers
(The TQCC of Veterinary and Comparative Oncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Veterinary Cooperative Oncology Group—Common Terminology Criteria for Adverse Events (VCOG‐CTCAE v2) following investigational therapy in dogs and cats119
Determining agreement between preoperative computed tomography lymphography and indocyanine green near infrared fluorescence intraoperative imaging for sentinel lymph node mapping in dogs with oral tu28
Contrast‐enhanced ultrasound for sentinel lymph node mapping in the routine staging of canine mast cell tumours: A feasibility study25
Outcome and prognosis for canine appendicular osteosarcoma treated with stereotactic body radiation therapy in 123 dogs19
Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector17
Evaluation of a modified proportional margin approach for complete surgical excision of canine cutaneous mast cell tumours and its association with clinical outcome17
Peripheral blood cell ratios as prognostic factors in canine diffuse large B‐cell lymphoma treated with CHOP protocol17
Prognostic significance of immunohistochemical markers and histological classification in malignant canine mammary tumours16
Outcome after surgical management of canine insulinoma in 49 cases15
To map or not to map the cN0 neck: Impact of sentinel lymph node biopsy in canine head and neck tumours14
Cyclooxygenase‐2 expression is associated with infiltration of inflammatory cells in oral and skin canine melanomas14
Outcome comparison between radiation therapy and surgery as primary treatment for dogs with periarticular histiocytic sarcoma: An Italian Society of Veterinary Oncology study13
Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant CSPG4‐DNA electrovaccination: A retro13
Clinical outcome in 23 dogs with exocrine pancreatic carcinoma12
Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase‐2 inhibitor and toceranib phosphate12
Safety and efficacy of stereotactic body radiation therapy (SBRT) for the treatment of canine thyroid carcinoma12
Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B‐cell lymphoma12
Long‐term survival of dogs with stage 4 oral malignant melanoma treated with anti‐canine PD‐1 therapeutic antibody: A follow‐up case report12
Statins downregulateYAPandTAZand exert anti‐cancer effects in canine mammary tumour cells11
Adherence to follow‐up recommendations for dogs with apocrine gland anal sac adenocarcinoma: A multicentre retrospective study10
Clinical presentation, treatment and outcome of canine malignant mesothelioma: A retrospective study of 34 cases10
Prognostic impact of clinical, haematological, and histopathological variables in 102 canine cutaneous perivascular wall tumours10
Neutrophil‐to‐lymphocyte ratio is an independent prognostic marker for feline mammary carcinomas10
Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials10
Kynurenine 3‐monooxygenase (KMO), and signal transducer and activator of transcription 3 (STAT3) expression is involved in tumour proliferation and predicts poor survi10
Standardisation of canine meningioma grading: Inter‐observer agreement and recommendations for reproducible histopathologic criteria10
A newly established canine NK‐type cell line and its cytotoxic properties9
Intraoperative assessment of canine soft tissue sarcoma by deep learning enhanced optical coherence tomography9
Prospective observational study of dogs with splenic mass rupture suggests potentially lower risk of malignancy and more favourable perioperative outcomes9
The effect of cannabidiol on canine neoplastic cell proliferation and mitogen‐activated protein kinase activation during autophagy and apoptosis9
Outcome, prognostic factors and histological characterization of canine gastrointestinal sarcomas9
Adjuvant doxorubicin vs metronomic cyclophosphamide and meloxicam vs surgery alone for cats with mammary carcinomas: A retrospective study of 137 cases9
Canine presumed glial brain tumours treated with radiotherapy: Is there an inferior outcome in tumours contacting the subventricular zone?9
Prognostic impact of bone invasion in canine oral malignant melanoma treated by surgery and anti‐CSPG4 vaccination: A retrospective study on 68 cases (2010–2020)9
Prognostic value of immunohistochemical markers in canine cutaneous mast cell tumours: A systematic review and meta‐analysis9
The role of toceranib phosphate in dogs with non‐mast cell neoplasia: A systematic review9
Evaluation of accuracy for 18F‐FDG positron emission tomography and computed tomography for detection of lymph node metastasis in canine oral malignant melanoma8
The oncogenic pathways of papillomaviruses8
BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: A retrospective study (2006–2019)8
Post‐operative complications following apocrine gland anal sac adenocarcinoma resection in dogs8
miR‐497 induces apoptosis by the IRAK2/NF‐κB axis in the canine mammary tumour8
Characterizing the molecular and immune landscape of canine bladder cancer8
Canine mammary tumours: Size matters–a progression from low to highly malignant subtypes8
Unconventional diets and nutritional supplements are more common in dogs with cancer compared to healthy dogs: An online global survey of 345 dog owners8
Evaluation of prognostic impact of pre‐treatment neutrophil to lymphocyte and lymphocyte to monocyte ratios in dogs with oral malignant melanoma treated with surgery and adjuvant CSPG4‐anti8
Minimally invasive ethyl cellulose ethanol ablation in domesticated cats with naturally occurring head and neck cancers: Six cats7
Diagnosis and histopathologic prognostication of canine melanocytic neoplasms: A consensus of the Oncology‐Pathology Working Group7
One‐year conditional survival of dogs and cats with invasive mammary carcinomas: A concept inspired from human breast cancer7
Response‐based modification of CHOP chemotherapy for canine B‐cell lymphoma7
Fasting reduces the incidence of vincristine‐associated adverse events in dogs7
The feasibility and utility of optical coherence tomography directed histopathology for surgical margin assessment of canine mast cell tumours7
Lifetime prevalence of malignant and benign tumours in companion dogs: Cross‐sectional analysis of Dog Aging Project baseline survey7
Long non‐coding RNA and transfer RNA‐derived small fragments in exosomes are potential biomarkers for canine oral melanoma7
Molecular differences in mitochondrial DNA genomes of dogs with malignant mammary tumours7
Carboplatin‐induced myelosuppression as related to body weight in dogs7
Genetic variants of BRCA1 and BRCA2 genes in cats with mammary gland carcinoma6
Outcome and postoperative complications in 73 dogs with thyroid carcinoma with gross vascular invasion managed with thyroidectomy6
Thymic epithelial tumours in 51 dogs: Histopathologic and clinicopathologic findings6
Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component6
JARID1‐targeted histone H3 demethylase inhibitors exhibit anti‐proliferative activity and overcome cisplatin resistance in canine oral melanoma cell lines6
Canine tonsillar neoplasia and tonsillar metastasis from various primary neoplasms6
Risk of bladder cancer and lymphoma in dogs is associated with pollution indices by county of residence6
Prognostic indicators for naïve canine non‐indolent T‐cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy6
Toosendanin‐induced apoptosis of CMT‐U27 is mediated through the mitochondrial apoptotic pathway6
Outcomes and prognostic factors in canine epitheliotropic and nonepitheliotropic cutaneous T‐cell lymphomas6
Risk factors and outcome in dogs with recurrent massive hepatocellular carcinoma: A Veterinary Society of Surgical Oncology case–control study6
Histologic grade has a higher‐weighted value than nodal status as predictor of outcome in dogs with cutaneous mast cell tumours and overtly metastatic sentinel lymph nodes6
Canine anal sac gland carcinoma with regional lymph node metastases treated with sacculectomy and lymphadenectomy: Outcome and possible prognostic factors6
Chemotherapy‐induced diarrhoea in dogs and its management with smectite: Results of a monocentric open‐label randomized clinical trial6
Feline and canine Merkel cell carcinoma: A case series and discussion on cellular origin6
Are B‐symptoms more reliable prognostic indicators than substage in canine nodal diffuse large B‐cell lymphoma6
Shear wave elastography of lymph nodes in dogs with head and neck cancer: A pilot study6
Extensive staging has no prognostic value in dogs with low‐risk mast cell tumours6
Response and outcome following radiation therapy of macroscopic canine plasma cell tumours6
Evaluation of the anti‐tumour activity of Coriolus versicolor polysaccharopeptide (I'm‐Yunity) alone or in combination with doxorubicin for canine splenic hemangiosarcoma6
Highly recurrent BRAF p.V595E mutation in canine papillary oral squamous cell carcinoma5
Evaluating optical coherence tomography for surgical margin assessment of canine mammary tumours5
Prognostic value of pretreatment plasma D‐dimer level in dogs with intermediate to high‐grade non‐Hodgkin lymphoma5
A prospective, multi‐centre, Veterinary Radiation Therapy Oncology Group study reveals potential efficacy of toceranib phosphate (Palladia) as a primary or adjuvant agent in the treatment of canine na5
Analysis of DNA methylation and TP53 mutational status for differentiating feline oral squamous cell carcinoma from non‐neoplastic mucosa: A preliminary study5
Optical coherence tomography imaging of excised canine apocrine gland anal sac adenocarcinoma tumours5
Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model5
Retrospective assessment of radiation toxicity from a definitive‐intent, moderately hypofractionated image‐guided intensity‐modulated protocol for anal sac adenocarcinoma in dogs5
Long‐term outcomes with conventional fractionated and stereotactic radiotherapy for suspected heart‐base tumours in dogs5
Comparison of pathologist review protocols for cytologic detection of prostatic and urothelial carcinomas in canines: A bi‐institutional retrospective study of 298 cases5
Axillary lymphadenectomy in dogs: A description of surgical technique5
A retrospective study of 101 dogs with oral melanoma treated with a weekly or biweekly 6 Gy × 6 radiotherapy protocol5
Outcomes of cats treated with maxillectomy: 60 cases. A Veterinary Society of Surgical Oncology retrospective study5
An open‐label dose escalation study evaluating tolerability and safety of a single 5‐days course of temozolomide in dogs with advanced cancer5
Ki‐67 assessment—agreeability between immunohistochemistry and flow cytometry in canine lymphoma5
Effect of simvastatin on cell proliferation and Ras activation in canine tumour cells5
Plasma 25‐hydroxyvitamin D and the inflammatory response in canine cancer5
Focused ultrasound tumour ablation in small animal oncology5
Treatment outcomes and target delineation utilizing CT and MRI in 13 dogs treated with a uniform stereotactic radiation therapy protocol (16 Gy single fraction) for pituitary mas5
0.038289070129395